![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XWPharma expects to use proceeds to advance clinical development of the company’s lead investigational programs: XW10172, a GABAB receptor agonist intended for the treatment of sleep disorders in narcolepsy, Parkinson’s disease and other neurodegenerative diseases.
Lead Product(s): XW10172
Therapeutic Area: Sleep Product Name: XW10172
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Panacea Venture
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 17, 2020